[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR105114A1 - Compuestos de aminopiridina sustituida con heteroarilo - Google Patents

Compuestos de aminopiridina sustituida con heteroarilo

Info

Publication number
AR105114A1
AR105114A1 ARP160101893A ARP160101893A AR105114A1 AR 105114 A1 AR105114 A1 AR 105114A1 AR P160101893 A ARP160101893 A AR P160101893A AR P160101893 A ARP160101893 A AR P160101893A AR 105114 A1 AR105114 A1 AR 105114A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
cycloalkyl
heteroaryl
oxetanyl
Prior art date
Application number
ARP160101893A
Other languages
English (en)
Inventor
Rao Polimera Subba
Kumar Sistla Ramesh
Sarkunam Kandhasamy
Reddy Paidi Venkatram
Kesavan Nair Satheesh
Wu Hong
B Santella Joseph
E Macor John
Hynes John
s gardner Daniel
V Duncia John
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR105114A1 publication Critical patent/AR105114A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o una sal de aquel, en donde: HET es un heteroarilo seleccionado de imidazo[1,2-b]piridazinilo y pirazolo[1,5-a]pirimidinilo, en donde el heteroarilo está unido al grupo piridinilo en el compuesto de la fórmula (1) mediante un átomo del anillo de carbono en el heteroarilo, y en donde el heteroarilo se sustituye con 0 a 2 Rᵇ; A es pirazolilo, imidazolilo o triazolilo, cada uno sustituido con 0 ó 1 Rᵃ; R³ es: (i) -CH₂CH₃, -CH(CH₃)₂, -CH₂CHF₂, -CH(CH₃)CH₂OH, oxetanilo, tetrahidropiranilo o C₃₋₅ cicloalquilo sustituido con 0 a 2 F; (ii) pirazolilo sustituido con 0 a 2 sustituyentes seleccionados independientemente de C₁₋₃ alquilo, C₁₋₃ hidroxialquilo, C₁₋₃ fluoroalquilo, oxetanilo, tetrahidrofuranilo y tetrahidropiranilo; Rᵃ es: (i) F, Cl, -OH, -CN, C₁₋₆ alquilo, C₁₋₄ fluoroalquilo, C₁₋₄ cianoalquilo o C₁₋₆ hidroxialquilo; o (ii) C₃₋₆ cicloalquilo, azetidinilo, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo, piperidinilo, piperazinilo, pirrolilo, pirrolidinonilo, morfolinilo, pirrolidinilo, fenilo, pirazolilo, imidazolilo, piridinilo o pirimidinilo, cada uno sustituido con 0 a 4 sustituyentes seleccionados independientemente de F, -CN, -OH, -NRʸRʸ, C₁₋₃ alquilo, C₁₋₃ fluoroalquilo, -CH(fenilo)₂, -O(C₁₋₄ alquilo), -C(O)(C₁₋₄ alquilo), -C(O)(C₁₋₄ deuteroalquilo), -C(O)(C₃₋₆ cicloalquilo), -C(O)O(C₁₋₄ alquilo), -C(O)NRʸRʸ, -C(O)(fenilo), -C(O)(piridinilo), -C(O)CH₂(C₃₋₆ cicloalquilo), -NHC(O)CH₃, -NHC(O)OCH₃, -NHC(O)OC(CH₃)₃, -S(O)₂(C₁₋₃ alquilo) y -OS(O)₂(C₁₋₃ alquilo); cada Rᵇ se selecciona independientemente de F, Cl, -CN, NH₂, -CH₃, -OCH₃ y ciclopropilo; y cada Rʸ es independientemente H o C₁₋₃ alquilo.
ARP160101893A 2015-06-24 2016-06-23 Compuestos de aminopiridina sustituida con heteroarilo AR105114A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1880DE2015 2015-06-24

Publications (1)

Publication Number Publication Date
AR105114A1 true AR105114A1 (es) 2017-09-06

Family

ID=56345252

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101893A AR105114A1 (es) 2015-06-24 2016-06-23 Compuestos de aminopiridina sustituida con heteroarilo

Country Status (9)

Country Link
US (1) US10202390B2 (es)
EP (1) EP3313844B1 (es)
JP (1) JP6720225B2 (es)
CN (1) CN108026099B (es)
AR (1) AR105114A1 (es)
ES (1) ES2822956T3 (es)
TW (1) TW201713663A (es)
UY (1) UY36747A (es)
WO (1) WO2016210037A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105112A1 (es) * 2015-06-24 2017-09-06 Bristol Myers Squibb Co Compuestos de aminopiridina sustituida con heteroarilo
AR105114A1 (es) 2015-06-24 2017-09-06 Bristol Myers Squibb Co Compuestos de aminopiridina sustituida con heteroarilo
JP6843775B2 (ja) * 2015-06-24 2021-03-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリール置換のアミノピリジン化合物
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2018209012A1 (en) 2017-05-11 2018-11-15 Bristol-Myers Squibb Company Thienopyridines and benzothiophenes useful as irak4 inhibitors
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
KR102659550B1 (ko) * 2018-08-13 2024-04-23 길리애드 사이언시즈, 인코포레이티드 Irak4 억제제로서의 피롤로[1,2-b]피리다진 유도체
EP3837012A1 (en) 2018-08-13 2021-06-23 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
EP3999512B1 (en) * 2019-07-18 2023-08-23 Bristol-Myers Squibb Company Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as irak4 inhibitors
CN114174304B (zh) * 2019-07-23 2024-05-17 百时美施贵宝公司 可用作irak4抑制剂的噻吩并吡啶基化合物和噻唑并吡啶基化合物
KR20220155295A (ko) * 2020-02-19 2022-11-22 누릭스 테라퓨틱스 인코포레이티드 인터류킨-1 수용체 관련 키나아제의 이작용성 분해제 및 이의 치료적 용도
CN113149995A (zh) * 2021-03-31 2021-07-23 安徽驱石医药科技有限公司 一种7-氟吡唑并[1,2-b]吡嗪-4-甲腈的合成方法及应用
JP2024531273A (ja) 2021-08-18 2024-08-29 ニューリックス セラピューティクス，インコーポレイテッド インターロイキン－１受容体関連キナーゼの二官能性分解剤及びその治療的使用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4541695B2 (ja) 2001-06-15 2010-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとしての５−（２−アミノピリミジン−４−イル）ベンズイソキサゾール
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
CA2490888C (en) 2002-06-28 2011-05-24 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxamide derivative
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CN1820001A (zh) 2003-07-10 2006-08-16 神经能质公司 经取代的杂环二芳基胺类似物
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20110021513A1 (en) * 2006-09-07 2011-01-27 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
EP2164841A1 (en) 2007-06-08 2010-03-24 Bayer CropScience SA Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2010058846A1 (ja) 2008-11-21 2010-05-27 アステラス製薬株式会社 ４，６-ジアミノニコチンアミド化合物
US8575153B2 (en) 2008-11-28 2013-11-05 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
BR112012010220A2 (pt) 2009-10-30 2021-02-23 Janssen Pharmaceutical N.V. piridinas fenóxi-substituídas como modulares do receptor opioide
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
JP2014515029A (ja) 2011-04-29 2014-06-26 アイカーン・スクール・オブ・メディシン・アト・マウント・シナイ キナーゼ阻害剤
ES2575604T3 (es) * 2012-01-13 2016-06-29 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa
CN104169275B (zh) 2012-01-13 2017-06-09 百时美施贵宝公司 用作激酶抑制剂的三唑取代的吡啶化合物
JP6109195B2 (ja) 2012-01-13 2017-04-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼ阻害剤として有用な複素環置換されたピリジル化合物
CA2890929A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
SG11201503397YA (en) * 2012-11-08 2015-05-28 Bristol Myers Squibb Co Heteroaryl substituted pyridyl compounds useful as kinase modulators
US9546153B2 (en) 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
UY35935A (es) * 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
JP6843775B2 (ja) * 2015-06-24 2021-03-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリール置換のアミノピリジン化合物
AR105114A1 (es) 2015-06-24 2017-09-06 Bristol Myers Squibb Co Compuestos de aminopiridina sustituida con heteroarilo

Also Published As

Publication number Publication date
CN108026099A (zh) 2018-05-11
JP2018524331A (ja) 2018-08-30
TW201713663A (zh) 2017-04-16
UY36747A (es) 2016-12-30
JP6720225B2 (ja) 2020-07-08
US10202390B2 (en) 2019-02-12
EP3313844B1 (en) 2020-08-26
CN108026099B (zh) 2020-07-10
ES2822956T3 (es) 2021-05-05
WO2016210037A1 (en) 2016-12-29
EP3313844A1 (en) 2018-05-02
US20180179213A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
AR105114A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR105113A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR101174A1 (es) Imidazopirazinas como inhibidores de lsd1
AR105112A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR101175A1 (es) Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
AR098991A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PE20160540A1 (es) Inhibidores de bromodominios
ME02423B (me) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
AR088235A1 (es) Derivados de pirazoloquinolina
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR091285A1 (es) Inhibidores de bromodominio y sus usos
PH12016501232A1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
SI3357922T1 (sl) 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino) pirido(2,3-D)pirimidin-7(8H)-on derivati in sorodne spojine kot CDK4 inhibitorji za zdravljenje tumorjev
PH12016502147A1 (en) Substituted 4-phenylpiperidines, their preparation and use
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
EA202091761A1 (ru) Комбинированная терапия для лечения гастроинтестинальных стромальных опухолей
AR094565A1 (es) Compuestos y métodos para tratar infecciones bacterianas

Legal Events

Date Code Title Description
FB Suspension of granting procedure